Clinical imaging · 2025
Cryoablation of bone, soft tissue, and nerve in the setting of uninterrupted systemic cancer therapies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sag Alan A, Barral Ernest, Ronald James, Oyediran Isaac O, Force Jeremy, Larrier Nicole A, Visgauss Julia, Kim Charles Y
Аннотация
PURPOSE: To assess safety of cryoablation in cancer patients receiving uninterrupted systemic cancer therapies with regard to wound healing.
MATERIALS AND METHODS: In this single-institution IRB-approved retrospective study, all patients (29/50 (58 %) female, mean age 61.9 +/- 11.3 years) undergoing cryoablation of bone, soft tissue, or nerve for symptomatic treatment while on uninterrupted systemic therapy between 2019 and 2022 were included for analysis. Charts were reviewed to identify post-cryoablation infection or wound healing complication within 90 days after cryoablation. All patients received routine prophylactic intraprocedural antibiotics; no patients were prescribed antibiotics post-procedure.
RESULTS: Sixty-nine cryoablations of bone (42/69, 61 %), soft tissue (17/69, 25 %) and nerve (10/69,14 %) were performed without interrupting ongoing traditional chemotherapy, targeted therapy, immunotherapy, investigational clinical trial therapy, or hormone therapy in 32/69 (35 %), 26/69 (38 %), 14/69 (20 %), 5/69 (7 %) respectively. There were 3/69 (4 %) patients with neutropenia (defined as absolute neutrophil count <1500 cells/mL). Agents known to delay wound healing (such as VEGF/R, E/FGFR inhibitors) or chronic steroids were not interrupted in 9/69 (13 %) and 36/69 (52 %) respectively. Prior to cryoablation, the treatment zone was previously embolized in 8/69 (12 %) and irradiated in 34/69 (49 %). By mean clinical follow up of 41 days (range, 1-98 days post-cryoablation), no procedure-site infections nor wound healing complications occurred.
CONCLUSION: Wound healing abnormalities were not observed when performing percutaneous cryoablation with uninterrupted systemic therapies in this study, even in treatment zones that had received radiotherapy and embolization.
MATERIALS AND METHODS: In this single-institution IRB-approved retrospective study, all patients (29/50 (58 %) female, mean age 61.9 +/- 11.3 years) undergoing cryoablation of bone, soft tissue, or nerve for symptomatic treatment while on uninterrupted systemic therapy between 2019 and 2022 were included for analysis. Charts were reviewed to identify post-cryoablation infection or wound healing complication within 90 days after cryoablation. All patients received routine prophylactic intraprocedural antibiotics; no patients were prescribed antibiotics post-procedure.
RESULTS: Sixty-nine cryoablations of bone (42/69, 61 %), soft tissue (17/69, 25 %) and nerve (10/69,14 %) were performed without interrupting ongoing traditional chemotherapy, targeted therapy, immunotherapy, investigational clinical trial therapy, or hormone therapy in 32/69 (35 %), 26/69 (38 %), 14/69 (20 %), 5/69 (7 %) respectively. There were 3/69 (4 %) patients with neutropenia (defined as absolute neutrophil count <1500 cells/mL). Agents known to delay wound healing (such as VEGF/R, E/FGFR inhibitors) or chronic steroids were not interrupted in 9/69 (13 %) and 36/69 (52 %) respectively. Prior to cryoablation, the treatment zone was previously embolized in 8/69 (12 %) and irradiated in 34/69 (49 %). By mean clinical follow up of 41 days (range, 1-98 days post-cryoablation), no procedure-site infections nor wound healing complications occurred.
CONCLUSION: Wound healing abnormalities were not observed when performing percutaneous cryoablation with uninterrupted systemic therapies in this study, even in treatment zones that had received radiotherapy and embolization.